Myelofibrosis Clinical Trials

Find Myelofibrosis Clinical Trials Near You

Clinical Epidemiology in Contemporary Patients With Myelofibrosis (ERNEST-3): A European LeukemiaNet (ELN) Observational Study

Status: Recruiting
Location: See all (27) locations...
Study Type: Observational
SUMMARY

Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027

• Age ≥ 18 years

• Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives

Locations
Other Locations
Armenia
Hematology Center after Prof.R.H. Yeolyan
RECRUITING
Yerevan
Germany
University Hospital Halle Department of Hematology/Oncology
NOT_YET_RECRUITING
Halle
University Medicine Hannover
RECRUITING
Hanover
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum
RECRUITING
Minden
Italy
A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia
RECRUITING
Alessandria
ASST Papa Giovanni XXIII, SC Ematologia
RECRUITING
Bergamo
Policlinico S. Orsola - Malpighi, Unità di Ematologia
RECRUITING
Bologna
Azienda Ospedaliero - Universitaria Policlinico Vittorio Emanuele - PO Gaspare Rodolico, Dipartimento di ematologia con Trapianto di midollo Osseo
RECRUITING
Catania
AOU Careggi di Firenze, Divisione di Ematologia
RECRUITING
Florence
ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia
RECRUITING
Milan
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ematologia
RECRUITING
Milan
Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo
RECRUITING
Milan
Fondazione IRCCS San Gerardo dei Tintori
RECRUITING
Monza
Azienda Ospedaliera Universitaria Federico II, Divisione di Ematologia
RECRUITING
Naples
Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia
RECRUITING
Novara
Fondazione IRCCS Policlinico San Matteo, Divisione di Ematologia
RECRUITING
Pavia
Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, UCSC Ematologia
RECRUITING
Roma
Policlinico Umberto I, Dipartimento Ematologia, Oncologia e Dermatologia
RECRUITING
Roma
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U
NOT_YET_RECRUITING
Torino
Ospedale Cardinale G. Panico
NOT_YET_RECRUITING
Tricase
Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di Ematologia
RECRUITING
Verona
Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia
RECRUITING
Vicenza
Poland
Department of Hematology, University Hospital, Jagiellonian University Medical College
RECRUITING
Krakow
Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University
RECRUITING
Wroclaw
Romania
Department of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute
RECRUITING
Bucharest
Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic
RECRUITING
Barcelona
Hematology and Hemotherapy Department, 12 de Octubre University Hospital
RECRUITING
Madrid
Contact Information
Primary
TIZIANO BARBUI, MD
tbarbui@fondazionefrom.it
0352675134
Backup
FENILI
sperimentazioni@fondazionefrom.it
Time Frame
Start Date: 2024-10-14
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 617
Related Therapeutic Areas
Myelofibrosis
Sponsors
Leads: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Collaborators: GlaxoSmithKline

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Who is this study for: Adult patients with Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Drug: Luspatercept
Study Phase: Phase 3

Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis

Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis

Who is this study for: Adult patients with chronic myelogenous leukemia and other hematologic malignancies
Enrollment Status: Recruiting
Publish Date: December 29, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Selumetinib
Study Phase: Phase 1

Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Enrollment Status: Recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Phase: Phase 2
View All